Xenon Pharmaceuticals Inc.
XENE
$55.00
-$0.78-1.40%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 44.62% | 47.46% | 35.25% | 50.87% | 38.31% |
| Gross Profit | -64.82% | -47.46% | -35.25% | -50.87% | -21.36% |
| SG&A Expenses | 25.12% | 22.57% | 15.42% | -0.81% | 28.71% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.99% | 41.68% | 30.76% | 36.36% | 35.90% |
| Operating Income | -54.43% | -41.68% | -30.76% | -36.36% | -23.20% |
| Income Before Tax | -62.29% | -50.61% | -42.96% | -46.48% | -35.99% |
| Income Tax Expenses | -702.11% | 113.98% | 311.56% | -87.99% | 3.64% |
| Earnings from Continuing Operations | -57.27% | -60.25% | -44.76% | -46.24% | -35.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -57.27% | -60.25% | -44.76% | -46.24% | -35.71% |
| EBIT | -54.43% | -41.68% | -30.76% | -36.36% | -23.20% |
| EBITDA | -55.03% | -42.11% | -31.07% | -36.71% | -23.31% |
| EPS Basic | -41.69% | -56.77% | -42.34% | -43.86% | -33.82% |
| Normalized Basic EPS | -46.19% | -47.35% | -40.56% | -44.09% | -34.09% |
| EPS Diluted | -41.69% | -56.77% | -42.34% | -43.86% | -33.82% |
| Normalized Diluted EPS | -46.19% | -47.35% | -40.56% | -44.09% | -34.09% |
| Average Basic Shares Outstanding | 11.00% | 2.22% | 1.70% | 1.65% | 1.41% |
| Average Diluted Shares Outstanding | 11.00% | 2.22% | 1.70% | 1.65% | 1.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |